Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- CGTX
- Price
- 1.46
- Stock movement up
- +0.04 (2.82%)
- Company name
- Cognition Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 128.88M
- Ent value
- 95.92M
- Price/Sales
- 515.52
- Price/Book
- 3.53
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 97.30%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CGTX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 515.52 |
| Price to Book | 3.53 |
| EV to Sales | 383.69 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 88.27M |
| EPS (TTM) | -0.36 |
| FCF per share (TTM) | -0.38 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 250.00K |
| Gross profit (TTM) | -238.00K |
| Operating income (TTM) | -44.85M |
| Net income (TTM) | -27.99M |
| EPS (TTM) | -0.36 |
| EPS (1y forward) | -0.34 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -95.20% |
| Operating margin (TTM) | -17940.40% |
| Profit margin (TTM) | -11194.40% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 39.82M |
| Net receivables | 1.90M |
| Total current assets | 42.88M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 512.00K |
| Total assets | 43.40M |
| Accounts payable | 827.00K |
| Short/Current long term debt | 380.00K |
| Total current liabilities | 6.65M |
| Total liabilities | 6.87M |
| Shareholder's equity | 36.53M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -29.53M |
| Capital expenditures (TTM) | 1.00K |
| Free cash flow (TTM) | -29.53M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -76.61% |
| Return on Assets | -64.49% |
| Return on Invested Capital | -76.26% |
| Cash Return on Invested Capital | -80.48% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.42 |
| Daily high | 1.49 |
| Daily low | 1.41 |
| Daily Volume | 720K |
| All-time high | 12.98 |
| 1y analyst estimate | 3.50 |
| Beta | 1.24 |
| EPS (TTM) | -0.36 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 1 Apr 2026 |
Downside potential
Loading...
Downside potential data
| CGTX | S&P500 | |
| Current price drop from All-time high | -88.75% | -0.89% |
| Highest price drop | -98.16% | -19.00% |
| Date of highest drop | 30 May 2025 | 8 Apr 2025 |
| Avg drop from high | -92.91% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
128.88M
Marketcap category
Small-cap
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Employees
25
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page